Pharvaris

Biotech & Life Sciences · Leiden, Netherlands · Founded 2015 · IPO 2021

Pharvaris is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel oral bradykinin B2 receptor antagonists. These antagonists are designed to treat hereditary angioedema (HAE) and other conditions mediated by the bradykinin B2 receptor. The company aims to provide an alternative to the currently available injected therapies, offering patients a more convenient oral treatment option. Pharvaris operates in the biopharmaceutical market, targeting patients suffering from rare and debilitating conditions. The company's business model revolves around the research, development, and eventual commercialization of its proprietary oral therapies. Revenue generation is anticipated through the successful development and approval of these therapies, followed by their marketing and sales. Pharvaris serves a niche market of patients with specific medical needs, focusing on innovative solutions that improve patient choice and quality of life. Keywords: bradykinin B2 receptor, hereditary angioedema, oral therapy, clinical-stage, biopharmaceutical, novel antagonists, patient choice, rare diseases, alternative treatment, drug development.

Valuation $1.99B

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier

Featured in

News Pharvaris prices $115M share offering to fund rare disease pipeline Jun 3, 2026

Investors

12 investors on Pharvaris's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 7 investors entered at this stage

Kurma Partners

EQT Life Sciences

venBio Partners

Series B+ 5 investors entered at this stage

General Atlantic

Viking Global Investors

Bain Capital Life Sciences

Cormorant Asset Management

Venrock Healthcare Capital Partners

Global footprint

Where Pharvaris has talent and traffic

Workforce by country

8 countries with
team presence

🇺🇸 United States43.5%

🇨🇭 Switzerland35.2%

🇳🇱 Netherlands16.7%

🇧🇪 Belgium0.9%

🇮🇹 Italy0.9%

Top 5 of 8 shown

Web traffic by country

5.5K monthly visits
across markets

🇺🇸 United States65.5%

🇮🇳 India18.2%

🇬🇧 United Kingdom16.4%

Top 3 markets shown

Talent graph

The shape of Pharvaris's talent

Dealroom maps Pharvaris's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

14 team members profilednamed & role-tagged by Dealroom

156 employeestotal headcount

7 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Pharvaris's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$32M patent portfolio · 24 active families

Estimated portfolio value

$32M

1.6% of market cap · 24.9× smaller than top peer BioNTech ($788M)

24 active patent families

Where Pharvaris innovates B2 receptorBradykininBradykinin B2 Receptor AntagonistsBradykinin Receptor AntagonistsBradykinin b2 receptor antagonist

Where Pharvaris concentrates vs peers

Each axis is a top-10 topic across Pharvaris and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Pharvaris

An AI-synthesized read of the highest-engagement posts about Pharvaris on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Pharvaris on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles